1. To study the metabolism of a,-antitrypsin in man, radioiodinated purified a,-antitrypsin of protease inhibitor type MM was injected intravenously into seven normal volunteer subjects of protease inhibitor type MM and plasma and urine radioactivity data were analysed. The purified glycoprotein inhibited trypsin and exhibited microheterogeneity characteristic of a,-antitrypsin on acid starch-gel electrophoresis.
Introduction
During the last decade interest in a,-antitrypsin has increased considerably as a consequence of the recognition that low concentrations of this glycoprotein in plasma and certain protease inhibitor (Pi) phenotypes (Fagerhol & Laurell, 1967; Fagerhol, 1968; Heimburger, 1972; Allen, Harley & Talamo, 1974; Kueppers, 1976 ) may be associated with liver and lung disease (Sharp, 1976) . The studies reported here were designed to provide comprehensive data on aspects of the metabolism of a,-antitrypsin in normal individuals which complement the data on the metabolism of this glycoprotein recently reported by Laurell, Nosslin & Jeppsson (1977) . Such data are necessary for the interpretation of data on the metabolism of a,-antitrypsin in patients with deficiency of this glycoprotein. In addition, in the light of the observations that (a) sialic acid appears to play an important role in the survival of other plasma glycoproteins in animals and (b) the sialic acid content of a,-antitrypsin in the deficiency state is reduced 139 6. A. Jones et al. (Miller, Kuhlenschmidt, Coffee, Kuo & Glew, 1976; Yoshida, Lieberman, Gaidulis & Ewing, 1976) , the effect of reducing the sialic acid content of a,-antitrypsin on the turnover of this particular glycoprotein in the plasma of normal individuals was also studied.
Subjects, materials and methods

Subjects
Six men, aged 19-22 years, and three women, aged 18-19 years, gave informed consent to the studies, which were approved by the Medical Research Committee of the National Institutes of Health. All were healthy, with normal routine haematological and serum biochemical values.
Protease inhibitor typing
Protease inhibitor phenotypes were determined by using the methods of starch-gel electrophoresis followed by crossed immunoelectrophoresis (Fagerhol & Laurel], 1967; Fagerhol, 1972a) and isoelectric focusing (Kueppers, 1976) . Sera of known protease inhibitor phenotypes were kindly supplied by Dr R. C. Talamo. a,-A ntitrypsin Serum concentrations. These were measured by radial immunodiffusion (Mancini, Carbonara & Heremans, 1965) , a commercial standard and partigen plates containing an anti-a,-antitrypsin antibody (Berhring Diagnostics, Somerville, N.J., U.S.A.) being used. At least three measurements of serum a,-antitrypsin concentration were made during each study of a,-antitrypsin turnover and the mean value was determined.
Tvpsin inhibitory capacity. The assay employed to measure the trypsin inhibitory capacity of serum and of purified a,-antitrypsin was that of Eriksson (1965) . The trypsin used was purified by affinity chromatography (Light & Liepnieks, 1974) . The purity of the trypsin was assessed by using the active-site titration method (Chase & Shaw, 1967) : it was 90% active.
Isolation. a,-Antitrypsin was isolated from a total of 200 ml of plasma obtained from a healthy blood donor whose plasma was negative for HBsAg by radioimmunoassay. Plasma was initially subjected twice to gel filtration . Fractions of the eluate which contained a,-antitrypsin, after concentration, were c ; passed over a concanavalin A affinity column. After washing of the column with phosphate buffer, glycoproteins bound to it were eluted with amethylglycoside (100 mmol/l) (Liener, Garrison & Pravda, 1973) . Fractions containing a,-antitrypsin after concentration and dialysis were then subjected twice to gradient DEAE column chromatography . The fractions containing a,-antitrypsin were collected and concentrated. The yield was 20%.
Desialylation. To desialylate a,-antitrypsin, 3.5 mg of the pure protein was incubated with 200 munits of neuraminidase in 1 ml of NaCl solution (154 mmol/l), pH 6-5, for 12 h at 26OC. The neuraminidase, which was kindly provided by Dr G. Ashwell, had been obtained from Clostridium perfringens and had been purified by affinity chromatography (Cuatrecasas & Illiano, 197 1). The purified enzyme was shown to be free from protease and aldolase activity. After the incubation neuraminidase was removed by gel filtration on a column of Sephadex G-150. The chromatographic behaviour and the tryptic inhibitory capacity of neuraminidase-treated and inact a,-antitrypsin were the same. The sialic acid content of both intact and desialylated a,-antitrypsin was determined (Warren, 1959) .
Radioiodination ofproteins
Portions (5-10 mg) of either a,-antitrypsin or desialylated a,-antitrypsin were radioiodinated with carrier-free lZsI (New England Nuclear, Boston, Mass., U.S.A.) or I3,I (Amersham Searle, Chicago, Ill., U.S.A.) with the iodine monochloride technique (McFarlane, 1964) . The level of iodination was on average 0-5-1.0 atom of iodine/molecule of protein. After dialysis human serum albumin (Behring Diagnostics, Somerville, N.J., U.S.A.) was added as camer. More than 99.5% of radioactivity in the preparations was precipitable by trichloroacetic acid (10 g/100 ml). Before intravenous administration preparations of radioiodinated protein were passed through Millipore filters (0.22 pm) and portions of each preparation were shown to meet USP specifications for sterility and apyrogenicity.
Design of studies
Throughout the period of the studies the diet of the female subjects consisted of approximately 1800 kcal. and 55 g of protein/day, and that of the male subjects approximately 2500 kcal. and 80 g of proteinlday. Uptake of radioiodine by the thyroid gland was blocked by administering non-radioactive iodide. a,-Antitrypsin turnover studies. These were carried out in seven subjects ( Table 1) . After a base-line sample of venous blood (6 ml) was taken, at zero time 50 pCi of 1311-or 1251-labelled a,-antitrypsin (containing less than 1 mg of a,-antitrypsin) was injected as a bolus into an arm vein. Timed blood samples (6 ml) were obtained from a vein in the opposite arm by separate venepunctures at 5 and 15 min. Two additional blood samples were obtained during the first 12 h. Thereafter blood samples were obtained twice daily for the next 5-7 days and then daily until termination of the study at 10-14 days. Timed complete individual urine collections were obtained during the first 1 or 2 days, after which complete 24 h urine collections were obtained for the remainder of the study.
Metabolism of desialylated a,-antitrypsin. This was studied in two subjects ( Table 2) . After a baseline specimen of venous blood (6 ml) was taken, at zero time 50 pCi of ')'I-labelled desialylated a,-antitrypsin was injected into an arm vein. Frequent specimens of blood (6 ml) were subsequently obtained through a heparin lock in a vein in the opposite arm during the ensuing 4 h. The time between samples was increased from 2 min initially to 15 min at the end of the study. Timed complete specimens of urine were collected for 18 h. In both subjects the pattern of uptake and decline of radioactivity in the liver was determined by placing a scintillation probe over the liver. An anterior gamma camera picture of the liver area was obtained during the first 45 min of the study. One week after the administration of 1311-labelled desialylated a,-antitrypsin, 1Z51-labelled intact alantitrypsin was administered intravenously to both subjects and plasma radioactivity determined during the subsequent 4 h.
Radioactivity counting
Portions of plasma (2 ml) and of urine (5 ml) together with appropriate standards were counted for radioactivity in a two-channel autogamma counter (Nuclear Chicago, Des Plaines, Ill., U.S.A.). After the count of plasma samples, the plasma proteins in each sample were precipitated by the addition of an equal volume of trichloroacetic acid (10 g/100 ml). After centrifugation and passage through a 0.22 pm Millipore filter, one-half of each clear supernatant was also counted for radioactivity.
Analysis of results
Plasma radioactivity was expressed as proteinbound radioactivity. Counts of radioactivity in each base-line plasma specimen, which were in all instances virtually indistinguishable from background counts, were subtracted from those in each of the other plasma specimens of that study.
Turnover of intact a,-antitrypsin. The Simulation, Analysis and Modeling (SAAM) program (Berman & Weiss, 1974 ) was used to determine the best fit of experimental measurements of plasma radioactivity to multiexponential functions. The fitted plasma radioactivity curves were normalized so that the sum of the coefficients of the exponential~ equalled unity. Values for extravascular radioactivity, as a fraction of the dose, were calculated by subtracting appropriate values for plasma radioactivity and cumulative excretion of radioactivity in urine from unity. The initial mixing volume of radioiodinated a,-antitrypsin was estimated by the principle of isotope dilution, with the extrapolated value for plasma radioactivity at zero time generated from the computer fit of the plasma radioactivity data. Values for the initial mixing volume approximated to those for plasma volume based on height, weight, sex and packed cell volume (Nadler, Hidalgo & Bloch, 1962) . The intravascular mass of a,-antitrypsin was determined by multiplying its mean concentration in serum by the initial mixing volume. Multiexponential analysis of the plasma radioactivity curve (Matthews, 1957) was used to calculate the fractional catabolic rate, the extravascular/intravascular mass ratio and the fractional transfer rates between the intravascular and extravascular pools. Values for the fractional catabolic rate were also estimated by the method of integrated rate equations (Nosslin, 1973) and urine/plasma ( U P ) radioactivity ratios (Berson & Yalow, 1957) , and additional calculations of the extravascular/intravascular mass ratio were made by the method of integrated rate equations (Nosslin, 1973) 
Results
Protease inhibitor types
The protease inhibitor type of all subjects studied and of the donor of the plasma used for isolation .of a,-antitrypsin was MM.
Trypsin inhibitory capacity
The trypsin inhibitory capacity of the serum of the subjects in whom turnover of a,-antitrypsin was studied varied between 0.78 and 1.68 mg of trypsin inhibited/ml (Table 1) . The plasma from which a,-antitrypsin was isolated inhibited 1.17 mg of trypsin/ml. Serum a,-antitupsin concentrations Serum a,-antitrypsin concentrations in the subjects in whom turnover of a,-antitrypsin was studied varied between 1.40 and 3-94 8/1 (Table 1) . The concentration of qantitrypsin in the plasma used to isolate a,-antitrypsin was 2.0 dl. Values for serum a,-antitrypsin concentration in each individual varied by less than or equal to f 5 % of the initial value during turnover studies. The reason for the observed variation in values for serum a,-antitrypsin concentration between individuals, notably the particularly high value in subject A.M., is not apparent. Factors known to influence the serum concentration of a,-antitrypsin such as the taking of oral contraceptives or the presence of an infection (Sharp, 1976) could not be implicated. There was a significant correlation between serum trypsin inhibitory capacity and serum a,-antitrypsin concentration (r = 0.96, P < 0.001). * Corresponding values for intact a,-antitrypsin in these subjects were 0.000697 (J.C.S.) and 0401068 min-I.
Properties of isolated a,-antitrypsin and radioiodinated a,-antitrypsin
The isolated a,-antitrypsin had a trypsin inhibitory capacity of 0.50 mg/mg of a,-antitrypsin. This material gave a single protein arc on crossed immunoelectrophoresis using an anti-(human whole serum) (Weeke, 1973 ) and a single protein band on polyacrylamide-gel electrophoresis (Brewer & Ashworth, 1969). The isolated a,-antitrypsin was also shown to retain the characteristic microheterogeneity of a,-antitrypsin, which is demonstrable by acid starch-gel electrophoresis (Fagerhol & Laurell, 1967; Fagerhol, 1972a) (Fig.   1) . No excess excretion of radioiodine in the urine was observed during the first 1-7-1.8 days of any of the studies (Fig. 2 ) .
Plasma disappearance curves of radioiodinated a,-antitrypsin
Two exponential functions were found to be both necessary and sufficient to define each plasma disappearance curve of radioiodinated a,-antitrypsin (Berman, Weiss & Shaha, 1962) . Designating the normalized coefficients of the first and second exponentials A and B respectively, and the corresponding rate constants a and / 3 respectively, the mean values for the parameters of the fitted curves were as follows: A = 0.592 f 0.0182 (SEM); a = -0.00124 f 0.000135 min-I; B = 0.408 f 0.0182; /3 = -0.000106 f 0.0000052 min-I. The corresponding fractional standard deviations were and 0.055 +_ 0.0039 respectively. Since the plasma disappearance curves of labelled a,-antitrypsin could be resolved into two exponentials it was appropriate to analyse the turnover data in terms of a two-pool model (Berman, 1963) (Fig. 3 ) . rate, half-life and synthetic rate of a,-antitrypsin are given in Table 1 . The fractional catabolic rate varied within +20% of the mean value. In contrast the mean concentrations of a,-antitrypsin in serum ranged from 38% below to 75% above the mean for the group. The serum a,-antitrypsin concentration varied independently of the fractional catabolic rate. Mean values for the fractional catabolic (Fig. 3) were 0.780 f 0.093 for A,, and 0.828 f 0.101 for Throughout each of the turnover studies the amount of radioactivity in urine over a given period expressed as a fraction of the mean plasma radioactivity during the same time interval (U/P radioactivity ratio) differed little from the corresponding ratio during other time intervals. Urine radioactivity had no such relationship to either extravascular (E) or whole-body radioactivity (Fig. 2) .
Furthermore, the mean value for intercepts with the ordinate of plots of (1 -P)/E against (JPdt)/E, which are equivalent to values for the ratio Aol/ (ao1 + A, , , ) (Nosslin, 1973) (Fig. 3 and Fig. 4) , was 0.976 f 0.023 (SEM).
Metabolism of desialylated qantitrypsin
Treatment of isolated pure a,-antitrypsin with neuraminidase resulted in an 82% reduction in its sialic acid content. Data on the metabolism of the labelled desialylated glycoprotein are shown in Table 2 . In both studies the initial rate of disappearance of the labelled desialylated protein is equivalent to the fractional catabolic rate and that of plot (6) the extravascular/intravascular pool ratio. The intercept of plot (a) with the ordinate is equivalent to ,l,,l/(&l + 43.
from the plasma was approximately 150 times greater than that of the labelled intact protein in the same subject. The rapid disappearance of l3II-labelled desialylated a,-antitrypsin from plasma coincided with a rapid uptake of radioactivity by the liver (Fig. 5) . The selective uptake of the label of desialylated a,-antitrypsin by the liver was sufficient to obtain a satisfactory gamma camera picture of the liver during the first 45 min of the study, 5 x lo4 counts being accumulated during this period. During the first 18 h of these studies 22% (J.C.S.) and 31% of the administered radioactivity was recovered from the urine.
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After the infusion of plasma of unspecified protease inhibitor type into three adult subjects who were homozygous for a,-antitrypsin deficiency, the halflives of u,-antitrypsin in plasma were found to be 5, 6 and 6 days (Makino & Reed, 1970) . These values for half-life are similar to most of the corresponding values obtained in this study and that of Laurell et al. (1977) and hence provide independent experimental support for the assumption that the behaviour in vivo of the radioiodinated u,-antitrypsin used in these studies is identical with that of native qantitrypsin. The microheterogeneity of a,-antitrypsin raises the possibility that this protein may consist of subpopulations of molecules which have different catabolic rates in vivo. However, at times greater than 3 days after the administration of labelled a,-antitrypsin no component of the plasma disappearance curves other than a terminal exponential was apparent. In addition, VIP radioactivity ratios varied little throughout each study. These observations suggest that if pure a,-antitrypsin does contain molecules that are catabolized at different rates, the differences in rates of catabolism are likely to be small.
The data on the metabolism of a,-antitrypsin presented in this paper apply only to the metabolism of the M-protein in subjects with the protease inhibitor phenotype MM. It is possible that u,-antitrypsin isolated from subjects with protease inhibitor phenotypes other than MM may be metabolized at different rates from the M-protein in individuals of protease inhibitor type MM. Recently this has been found to be the case for the Zprotein, which was cataboliied at a more rapid rate than the M-protein in a normal individual (Laurell et al., 1977) . Conversely the M-protein may be metabolized at different rates in subjects with phenotypes other than MM. While the protease inhibitor phenotype of the plasma infused into the a,-antitrypsin-deficient subjects in the study of Makino t Reed (1970) was not given, it is most probable that it was MM (Webb, Hyde, Schwartz, Hall, Condemi BC Townes, 1973; Rynbrandt, Ihrig & Kleinerman, 1975; Talamo, Langley, Levine & Kazemi, 1972; Fagerhol, 1972b; Pierce, Eradio & Dew, 1975) and the subjects studied probably had the phenotype ZZ. It follows that the similarities between values for the half-life of a,-antitrypsin in their study and corresponding values in the present investigation and that of Laurell et al. (1977) suggest that the rate of catabolism of the M-protein is not markedly different in individuals with the MM and 22 phenotypes. It appears from the results of this study that the fractional catabolic rate of a,-antitrypsin is independent of its serum concentration. This inference is also supported by the finding of a constant terminal monoexponential decline in the serum concentration of a,-antitrypsin after plasma from normal donors was infused into a,-antitrypsin-deficient subjects (Makino & Reed, 1970) . The apparent lack of relationship between the fractional catabolic rate of a,-antitrypsin and its serum concentration suggests that a constant volume of plasma is cleared of a,-antitrypsin per unit time by some mechanism which is independent of the concentration of a,-antitrypsin. A possible mechanism might be pinocytosis followed by intracellular catabolism in lysosomes whose catabolic capacity is not saturated by the a,-antitrypsin concentrations in this study (Waldmann & Strober, 1969) .
Throughout the turnover studies the amount of radioactivity in urine collections bore a constant relationship to plasma radioactivity, but not to whole-body or extravascular radioactivity. This is strong evidence that catabolism of a,-antitrypsin occurs either within the intravascular pool or in close relationship to it (McFarlane, 1963; Waldmann & Strober, 1969) . Furthermore, the ratio Aol/(~,,l + A, J approximated closely to 1.0. This suggests that the value of A,, in the two-pool model of a,-antitrypsin metabolism approximates to zero and, hence, that no appreciable extravascular catabolism of this protein occurs in normal subjects.
The very rapid removal of desialylated a,-antitrypsin from the plasma extends to man a similar observation made with human a,-antitrypsin in the rabbit (Miller et al., 1976) . The scintillation probe and gamma camera data indicate that the liver is the primary site of uptake of desialylated a,-antitrypsin. Assuming a value of 11.9 ml min-' kg-' for the hepatic plasma flow in normal male subjects (Martin, Mikulecky, Blaschke, Waggoner, Vergalla & Berk, 1975) , the data indicate that the liver extracts approximately 45% of the desialylated a,-antitrypsin presented to it in hepatic plasma. The effect of desialylation of a,-antitrypsin on the metabolism of this glycoprotein appears to be analogous to the effects of desialylation on the metabolism of other glycoproteins in animals (Morell, Gregoriadis, Scheinberg, Hickman & Ashwell, 1971; . Although in this study 82% of the sialic acid content of a,-antitrypsin was removed, the removal of only a few of the several sialic acid residues present in a glycoprotein molecule can be sufficient to result in its accelerated removal from plasma (van den Hamer, Morell, Scheinberg, Hickman & Ashwell, 1970) . This phenomenon has been shown to depend on the interaction between exposed galactose residues on the desialylated glycoprotein molecule and specific sialic acid-containing membrane receptor sites for these residues on the plasma membrane of hepatocytes (Pricer & Ashwell, 1971 , 1976 Hudgin, Pricer, Ashwell, Stockert & Morell, 1974; . The results of the present study suggest that receptor sites for desialylated glycoproteins exist in the human liver. After the administration of labelled desialylated a,-antitrypsin, measurements of changes in radioactivity in the liver probably reflect the metabolism of this protein in lysosomes of hepatocytes (La Badie, Chapman & Aronson, 1975) . Measurements of such changes in radioactivity may have clinical applications (van Rijk L van den Hamer, 1976).
The demonstration that a diminished sialic acid content of a,-antitrypsin can be associated with an increased rate of catabolism of a,-antitrypsin suggests that the low serum concentration of a,-antitrypsin in a,-antitrypsin deficiency could be due, at least in part, to the rapid removal by the liver of a structurally abnormal a,-antitrypsin in the circulation. Although unlikely, the possibility that such a process may be related to the presence of globules of a,-antitrypsin material in periportal hepatocytes in a,-antitrypsin deficiency (Sharp, 1976; Bhan, Grand, Colten t Alper, 1976) has not been excluded. The sialic acid content of the Z-protein in plasma has been shown to be appreciably lower than that of the M-protein (Miller et al., 1976; Yoshida et al., 1976) . However, in the rabbit (Miller et al., 1976) and one human subject (Laurell et al., 1977 ) the survival of the human Zprotein in plasma, while less than that of the human M-protein, was not reduced to the same extent as that of desialylated M-protein in this study. These observations imply that the low sialic acid content of the intact Z-protein, in contrast to neuraminidase-treated a,-antitrypsin, is not associated with exposed galactose residues. Indeed, the carbohydrate moiety of the Z-protein is deficient not only in sialic acid but also in galactose, mannose and glucosamine (Miller et al., 1976) .
Appendix
The method of integrated rate equations proposed by Nosslin (1973) requires determination of values for (1 -P)/E, (IPdt)/E and (IEdt)/E from experimental values of plasma and urine radioactivity expressed as fractions of the administered dose. In practice, these values can be generated as follows. Values for P and J P d t at the times at which each urine collection was completed are calculated analytically from the normalized parameters of the computer-fitted plasma radioactivity curve: p = Ae-at + Be-W
Values for E at the same times are derived by subtracting from unity appropriate values for P and the cumulative excretion of radioactivity in urine. 
